A new human challenge
A new human challenge: Human challenge studies involve exposing participants to a virus or other pathogens in order to study its effects on the human body A worker takes a swab sample for a Covid-19 test at a mobile testing site in Beijing.
A new human challenge study published in the journal Nature Medicine recently revealed that it takes just a tiny virus-laden droplet to infect someone with Covid-19. Human challenge studies involve exposing participants to a virus or other pathogens in order to study its effects on the human body.
‘Human challenge’ study offers valuable insights into Covid infection
The study began on March 31 with 36 volunteers between the ages of 18 and 29 years, with no evidence of previous infection or vaccination. Participants were screened for comorbidities, being overweight, having reduced kidney or liver function, or having any heart, lung, or blood problems — all considered risk factors for severe Covid-19 infection. Post the screening, written informed consent was also obtained from each participant.
Human Challenge Trials for Vaccine Development: regulatory considerations
The study was conducted in 10 phases. The first 10 infected volunteers were given the antiviral drug redeliver to reduce their chances of progressing to severe disease. The volunteers were introduced to the virus via a tiny drop of fluid containing the originally detected strain of the virus through a long, thin tube inserted into their nose. They were also closely, medically monitored for 24 hours a day at London’s Royal Free Hospital’s quarantine unit which had special airflow to keep the virus from escaping.
First human challenge study of Covid-19 yields valuable insights into how we get sick
The following were some of its findings:
*Eighteen (~53%) participants became infected, with viral load (VL) rising steeply and peaking at ~5 days after inoculation.
*Virus was first detected in the throat but rose to significantly higher levels in the nose
*Viable virus was recoverable from the nose up to ~10 days after inoculation, on average
*Mild-to-moderate symptoms were reported by 16 (89%) infected participants, beginning 2–4 days after inoculation, whereas two (11%) participants remained asymptomatic (no reportable symptoms).
*Anosmia (loss of sense of smell) or dysosmia (disordered smell perception) developed more slowly in 15 (83%) participants.
New human challenge trial in the UK to study immune response that can prevent Covid reinfection
The human challenge trial by Oxford University researchers will re-infect participants with Covid-19 and will study their immune response before and after the exposure.
New Delhi: A new human challenge trial has been launched in the UK to study the immune response required to protect people against Covid-19 reinfection. In a human challenge trial, according to the World Health Organization, “participants are intentionally challenged (whether or not they have been vaccinated) with an infectious disease organism”. Accordingly, participants of the UK study will be infected with Covid-19 to study their immune response.